Duality Biologics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An oncology-focused biotech developing novel antibody-drug conjugates (ADCs).
Oncology
Technology Platform
Integrated ADC platform for the discovery and optimization of novel antibodies, linkers, and cytotoxic payloads.
Opportunities
Strong and growing interest from large pharma in partnering for or acquiring novel ADC assets and platforms.
Risk Factors
Technical complexity and risk of clinical failure due to narrow therapeutic windows or unforeseen toxicities.
Competitive Landscape
Competes in a hotly contested but high-potential global ADC landscape with numerous biotech and pharma players.